BIOCRYST PHARMACEUTICALS INC: RA CAPITAL MANAGEMENT, L.P. amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
RA Capital Management, L.P. amended its Schedule 13G stake filing for BioCryst Pharmaceuticals Inc., disclosing the change in a filing with the SEC under accession number 0001346824-26-000275. The amendment updates the investment firm's reported ownership position in the drugmaker, though the filing summary did not specify the revised share count or percentage. The disclosure matters because 13G amendments signal shifts in passive or institutional ownership that can influence BioCryst's shareholder base and governance dynamics. Investors will watch for the detailed filing to confirm whether RA Capital increased, reduced or maintained its stake, and for any subsequent 13D or 13G filings that clarify intent.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
RA Capital Management, L.P., BioCryst Pharmaceuticals Inc